The economic burden of moderate-to-severe rheumatoid arthritis in Spain: the CIARA study

Switching to advanced therapies reduced out-of-pocket expenses and productivity losses. Although this reduction did not offset higher pharmaceutical spending, it may reflect clinical improvements.